Novo Nordisk A/S shares in the U.S. slumped Friday after a Phase 3 trial of its experimental heart drug failed [1, 2].
The setback represents a significant blow to the Danish pharmaceutical company's efforts to expand its portfolio beyond diabetes and obesity treatments. A failure in a late-stage trial often results in the loss of billions in potential future revenue and research investments.
The trial, known as ZEUS [4], tested the drug ziltivekimab [5]. According to company data, the study did not demonstrate a reduction in cardiovascular deaths or major adverse cardiovascular events [3]. This outcome occurred despite the drug achieving the expected biological response during the trial process [3].
Market reaction was immediate. U.S.-listed shares closed 8.8 percent lower [1], though some reports rounded the decline to roughly nine percent [1]. The stock volatility followed the announcement on July 31, 2026 [2].
Novo Nordisk has faced a series of challenges recently, and this trial failure adds to the company's existing woes [1]. While the company remains a dominant force in the healthcare sector, the ZEUS results indicate that ziltivekimab may not provide the clinical benefit required for regulatory approval and commercial viability.
The company's stock performance on the New York Stock Exchange reflected investor disappointment in the drug's inability to improve patient outcomes in the heart-disease category [1].
“The ZEUS Phase 3 trial did not demonstrate a reduction in cardiovascular deaths.”
The failure of the ZEUS trial limits Novo Nordisk's ability to diversify its revenue streams. By failing to prove that ziltivekimab reduces major adverse cardiovascular events, the company loses a key opportunity to penetrate the heart-drug market, leaving it more reliant on its existing GLP-1 success for growth.
